DoD Peer Reviewed Medical, Technology Therapeutic Development Award | HT9425 23 PRMRP TTDA

Opportunity Information: Apply for HT9425 23 PRMRP TTDA

The DoD Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (TTDA) is a Department of Defense funding opportunity focused on moving strong preclinical research results toward tangible medical products that can eventually be used in real-world clinical settings. The core idea is translation: taking promising laboratory or preclinical findings and pushing them along the development pathway into a deliverable product with clear clinical application. The intended outputs can include technologies or therapeutics that support prevention, detection, diagnosis, treatment, or improvements in quality of life, but the proposed product must align with one of the FY23 PRMRP Topic Areas and also fit within one of the FY23 PRMRP Strategic Goals. In other words, applicants are expected to demonstrate a tight connection between the proposed development work, the program's stated priorities, and the specific disease or condition being addressed.

A defining feature of the TTDA is that it is product-driven rather than purely discovery-driven. This mechanism is meant for projects that are beyond basic early exploration and are ready for development steps that reduce risk and increase readiness for later clinical use. Successful projects typically present a credible development plan, a clear description of the product and its intended use, and a pathway showing how the work will advance the technology or therapeutic toward clinical application. The opportunity emphasizes practical impact, which includes thinking through how the product would ultimately be used in medical care, what problem it solves, and why it is likely to meet a real need.

The award is explicitly oriented toward the health care needs of military Service Members, Veterans, and other eligible beneficiaries. That focus shapes the kinds of problems and product profiles that fit best, such as solutions that address conditions relevant to military populations, improve readiness and recovery, or better manage long-term health impacts that affect those communities. Applicants should be able to explain the military relevance in a concrete way, such as by describing the affected population, the operational or clinical context, and how the proposed product could make a meaningful difference for those end users.

A critical boundary of this funding mechanism is that it cannot be used to conduct clinical trials. That restriction signals that the TTDA is intended for preclinical and translational development activities that prepare a product for later clinical evaluation, but do not include human clinical trial execution under this particular award. Projects should therefore be structured around development work that advances readiness without crossing into clinical trial activities, such as refining prototypes, optimizing formulations, completing key nonclinical testing, validating performance, generating data to support future regulatory steps, or other activities that move a candidate product closer to being clinically testable.

Administratively, this opportunity was released by the Department of Defense (Department of the Army, USAMRAA) under funding opportunity number HT9425-23-PRMRP-TTDA, within the Science and Technology and other Research and Development category (CFDA 12.420). The funding instruments listed include grants and cooperative agreements, meaning selected projects may be supported either through a standard grant relationship or through a cooperative structure where the government has more substantial involvement during project performance. Eligibility is described as unrestricted, which generally indicates that a wide range of applicant organizations may apply, subject to any specific limitations or clarifications contained in the full announcement.

The posting lists an expected total of about 20 awards. It also shows an award ceiling of 0, which typically indicates that the ceiling was not specified in the summarized field and would need to be confirmed in the full funding announcement or associated program guidance. The opportunity was created on January 31, 2023, with an original closing date of May 31, 2023, which places it in the FY23 PRMRP cycle.

Overall, the TTDA is best understood as a bridge between promising preclinical science and a clinically relevant product that is being actively developed with a defined intended use, a milestone-driven plan, and a clear line of sight to future clinical application, while staying firmly on the preclinical side by excluding clinical trials from the scope of work.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Medical, Technology Therapeutic Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jan 31, 2023.
• Applicants must submit their applications by May 31, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 20 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 PRMRP TTDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: